The Life Science Funding Trends Forum for the 4th edition
- marketing81685
- Nov 20
- 2 min read
The Life Sciences Funding Forum is back for its 4th edition, bringing together investors, researchers, entrepreneurs, and decision-makers to discuss and debate on the challenges and opportunities in life science fundraising. This must-attend event is your opportunity to network, exchange ideas, and discover the next big fundraising trends in life sciences.
December 10th 2025, 1 - 5pm at Musée de la santé Armand-Frappier
We are pleased to already confirm the participation of Roberto Bellini (BSQUARED Capital), Mounia Azzi, PhD (AdBio partners), Youssef Lemgendez, CPA, MBA ( Fonds de solidarité FTQ), Jamie Stiff (Genesys Capital), Michael Mee (Amplitude Ventures), Suman Rao, PhD (Lumira Ventures), Samir Mounir, Ph.D., MBA. (Desjardins) and Francois-Thomas Michaud (Feldan Therapeutics ǀ Feldan Thérapeutiques) with additional speakers to be announced shortly.
The Life Sciences Funding Forum will be followed by the 2025 Life Sciences & Biotechnology Cocktail, taking place right next door at the Biodome.
The Life Sciences Funding Forum will be followed by the 2025 Life Sciences & Biotechnology Cocktail, taking place right next door at the Cosmodome.
What to expect ?
A session dedicated to looking back at the past year through the perspective of leading venture capitalists and the financial ecosystem.
The discussion will walk participants through the major developments and observations that marked 2025, highlighting what stood out for investors, what defined the funding landscape, and what elements will matter moving into the next cycle.
This section focuses on the key themes and areas that will be important in 2026.
It will outline the topics industry players are paying attention to, the shifts that may influence the coming year, and the perspectives shaping how companies and investors prepare for what’s ahead.
A conversation dedicated to spotlighting the journey of Feldan Therapeutics.
This segment will bring together the company’s CEO and key investors to walk through the important stages of their progression, what contributed to their success, and how their experience can inspire and inform other life sciences companies.
Comments